Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
ENTR-601-44
Entrada Therapeutics
Duchenne Muscular Dystrophy (DMD)
1 trial -
ENTR-601-44, SODIUM CHLORIDE
Entrada Therapeutics
Duchenne Muscular Dystrophy
1 trial -
ENTR-601-45
Entrada Therapeutics
Duchenne Muscular Dystrophy (DMD)
1 trial -
Encorafenib + Binimetinib
Regeneron UK Limited
Melanoma BRAF V600E/K Mutated
1 trial -
Experimental: CHF6001 3200 μg
Chiesi Farmaceutici S.p.A.
Uncontrolled Asthma
1 trial -
First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression (TEMOTRAD01)
Pari Pharma GmbH
Adults with non-contrast-enhancing diffuse brainstem gliomas with non-threatening infiltrative clinical and/or radiological progression, Adult brain stem gliomas
1 trial -
GADOTERIC ACID , PARACETAMOL , coramitug, CETIRIZINE , SODIUM CHLORIDE
NovoThirteen
Participants with transthyretin amyloid cardiomyopathy (ATTR CM)
1 trial -
GADOTERIC ACID, [18F]fludarabine
Pari Pharma GmbH
Patients with newly diagnosed primary central nervous system lymphoma naïve to surgery, radiotherapy or chemotherapy
1 trial -
GLPG1690 600 mg QD
Lakefront Biotherapeutics NV
Idiopathic Pulmonary Fibrosis
1 trial -
GSK256066
GlaxoSmithKline
Asthma
1 trial -
Herceptin 150 mg powder for concentrate for solution for infusion, Enhertu 100 mg powder for concentrate for solution for infusion, Fluorouracil Injection, 50 mg/ml, solution for injection, Ziihera 300 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Xeloda 500 mg film-coated tablets, Xeloda 150 mg film-co
Boehringer Ingelheim
gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, esophageal adenocarcinoma
1 trial -
IFOSFAMIDE, CISPLATIN, PACLITAXEL, METHYLPREDNISOLONE, RANITIDINE, MESNA, APREPITANT, DEXCHLORPHENIRAMINE MALEATE
Ningbo Cancer Hospital
Penis carcinoma
1 trial -
INAVOLISIB, FULVESTRANT, INAVOLISIB
Hoffmann-La Roche
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-Mutated, hormone receptor-positive (HR-Positive), human epidermal growth factor receptor 2 (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
1 trial -
INDV-6001
Indivior Pty Ltd
Moderate to Severe Opioid Use Disorder
1 trial -
INFLIXIMAB, RoActemra 20 mg/mL concentrate for solution for infusion
Pari Pharma GmbH
Takayasu arteritis
1 trial -
IPN60300
Ipsen
Advanced or metastatic solid tumours
1 trial -
IRINOTECAN, FLUOROURACIL , CETUXIMAB , ENCORAFENIB , SODIUM FOLINATE
Fondazione Telethon ETS
Patients affected by mCRC harbouring BRAF V600E
1 trial -
Ibrutinib 560 mg
United Therapeutics Europe Ltd
Mantle Cell Lymphoma
1 trial -
Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, BGB-11417, DEXAMETHASONE , Kyprolis 60 mg powder for solution for infusion
BEONE MEDICINES AUS PTY LTD
relapsed or refractory multiple myeloma
1 trial -
Inhixa 4,000 IU (40 mg)/0.4 mL solution for injection in pre-filled syringe, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, REGN7508
Lacuna Pharma Pty Ltd
Thromboembolic disease
1 trial -
Isatuximab, Kyprolis 60 mg powder for solution for infusion, METHYLPREDNISOLONE , MONTELUKAST , DexaGalen® 8 mg injekt Injektionslösung, DIPHENHYDRAMINE , Dexamethason 4 mg JENAPHARM®, Dr. Reddy's Carfilzomib, PARACETAMOL
Sanofi-aventis Healthcare Pty Ltd
Cancer - Relapsed/refractory multiple myeloma
1 trial -
KAE609
Novartis Pharmaceuticals
Malaria
1 trial -
KAE609
Novartis Pharmaceuticals
Cure Rate
1 trial -
KPT-8602
Karyopharm Therapeutics Inc
Relapsed/Refractory Multiple Myeloma (RRMM)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources